Healthcare Scan

Scan

Healthcare Scan

Scan symbols 19
ABBVABTAMGNBIIBCVSDXCMGILDISRGJNJLLYMDTMRKMRNAPFESYKTMOUNHVEEVVRTX
Watchlists 1
@healthcare-scan
raw scan snapshot — prices as of scan date, not live 25 rows · screens, not recommendations superseded by2026-04-26-healthcare-scanported fromresearch/classic/scans/_archive/2026-03-31-healthcare-scan.mdscan slughealthcare-scansource typescan-archive

Healthcare is a sector in violent rotation: JNJ, PFE, MRK, and MRNA are the clear winners (strong-up, golden crosses, near 52wk highs), while medtech and managed care are getting obliterated — UNH down -55% from peak, ABT at RSI 27.9, SYK/ISRG/DXCM in strong-down with death crosses. This is not a sector call, this is stock selection required.

Price Table

Symbol Price RSI vs SMA20 7D% 30D% 3M% Trend
MRK $120.10 60.0 +3.1% +1.69% -0.35% +14.94% strong-up
PFE $27.88 59.6 +2.9% +3.12% +2.27% +13.84% strong-up
JNJ $243.08 58.9 +1.2% +3.13% -2.20% +18.08% strong-up
MRNA $50.07 48.5 -5.3% -6.37% -5.26% +69.79% strong-up
ABBV $216.49 48.6 -0.6% +4.25% -7.59% -4.49% weak-down
GILD $138.20 43.6 -2.4% -0.69% -7.36% +13.23% weak-down
AMGN $351.57 42.4 -2.5% -0.23% -8.85% +8.16% weak-down
BIIB $179.67 43.2 -3.2% +1.92% -4.46% +2.09% weak-down
LLY $916.02 40.9 -3.2% -1.58% -10.02% -14.62% weak-down
VRTX $445.47 42.8 -3.3% -0.79% -8.35% -1.74% weak-down
TMO $489.11 46.8 +0.7% -0.56% -3.73% -15.51% down
CVS $71.76 40.2 -3.4% -1.45% -12.12% -8.83% down
UNH $269.69 42.8 -2.9% -3.24% -7.85% -17.67% strong-down
VEEV $174.60 38.8 -5.1% -1.72% -3.78% -21.78% strong-down
MDT $86.03 34.1 -2.1% -1.48% -11.59% -9.71% down
DXCM $63.35 36.6 -4.9% -6.71% -14.14% -4.55% strong-down
ISRG $460.17 35.2 -3.8% -4.27% -7.27% -18.75% strong-down
SYK $325.95 30.6 -5.3% -1.01% -15.78% -7.26% strong-down
ABT $101.45 27.9 -5.7% -1.34% -11.10% -18.62% strong-down

Tier Analysis

Momentum Leaders (RSI > 55) — Traditional Pharma Winning

  • MRK (60.0): +14.9% in 3M, strong-up, golden cross, +3.1% above SMA20. -4% from 52wk high. Alpha1Y +23.3% vs SPY. Keytruda oncology franchise delivering. Near resistance — trim on strength or hold through.
  • PFE (59.6): +13.8% in 3M, strong-up, golden cross. Only -1.5% from 52wk high — essentially at peak. The Pfizer comeback is real: post-COVID portfolio rationalization + Seagen oncology assets. +12.3% above SMA200.
  • JNJ (58.9): +18.1% in 3M, strong-up, golden cross. +24.2% above SMA200 — massive structural support. Alpha1Y +33.5%. J&J's diversified pharma + medtech (ex-medtech spin-off optionality) is the cleanest large-cap healthcare story. Near 52wk high (-3.4%).
  • MRNA (48.5): The quarter's biotech bombshell — +69.8% in 3M. Strong-up, golden cross, +50.3% above SMA200. Recent -6.4% week is a shakeout in a raging bull. mRNA platform revival beyond COVID.

Large-Cap Biopharma Consolidating (RSI 40-50)

  • ABBV (48.6): -7.6% in 30D but still golden cross and above SMA200 (+1.2%). Best risk/reward in large-cap given 5Y track record. Skyrizi/Rinvoq offsetting Humira biosimilar erosion.
  • GILD (43.6): +13.2% in 3M but -7.4% in 30D — pullback in uptrend. +12.8% above SMA200, golden cross. Antiviral + HIV + oncology pipeline — undervalued relative to earnings power.
  • AMGN (42.4): +8.2% in 3M, -8.9% in 30D. +11.6% above SMA200, golden cross. Weight loss pipeline (MariTide) is the optionality narrative.
  • BIIB (43.2): +2.1% in 3M, -4.5% in 30D. Above SMA200 (+13.2%), golden cross. Leqembi Alzheimer's ramp is a long-duration story.
  • LLY (40.9): The GLP-1 empire at -14.6% in 3M — pulling back hard. But +2.4% above SMA200 means structural support is right here. If SMA200 holds, this is the decade's best pharma buy. If it breaks, more pain ahead. RSI 40.9 approaching oversold.
  • VRTX (42.8): CF monopoly + pain pipeline (suzetrigine). -8.4% in 30D but +1.6% above SMA200, golden cross. Pipeline de-risking should re-rate.
  • TMO (46.8): Life science tools. -7.1% below SMA50, -5.3% below SMA200. Down trend. The post-COVID tools normalization is grinding on.

Broken / Oversold (RSI < 40)

  • CVS (40.2): PBM regulatory pressure + Aetna losses compounding. -12.1% in 30D, -8.8% in 3M. Down trend, -15.7% from 52wk high. Healthcare benefits under political attack.
  • VEEV (38.8): CRM for pharma — strong-down, death cross, -30.3% below SMA200. -43.8% from 52wk high. Cloud software derating hitting healthcare IT hard.
  • UNH (42.8): Managed care is in structural crisis. Strong-down, death cross, -12.7% below SMA200. -55.5% from 52wk high. DOJ/regulatory investigation + CEO tragedy aftermath + medical cost ratio blowout.
  • MDT (34.1): Medical devices breaking down. -9% below SMA50, -7.5% below SMA200. -19.1% from 52wk high. Down trend, not quite death cross but close.
  • DXCM (36.6): CGM competition intensifying. Strong-down, death cross, -11.8% below SMA200. -29.6% from 52wk high. Abbott's FreeStyle Libre winning share.
  • ISRG (35.2): Robotic surgery leader getting valuation reset. Strong-down, death cross, -9.2% below SMA200. -23.8% from 52wk high. RSI 35 approaching oversold — but structure is broken.
  • SYK (30.6): RSI 30.6 — technically oversold. But strong-down, death cross, -11.9% below SMA200. -19.5% from 52wk high. Orthopedic/surgical devices in a prolonged drawdown.
  • ABT (27.9): RSI extreme — most oversold name in the entire healthcare scan. Strong-down, death cross, -18.1% below SMA200. -27.1% from 52wk high. Diabetes devices + diagnostics losing momentum. Warning: deeply oversold can mean approaching washout lows — but structure is fully broken.

Entry Zones

Stock Entry Range Thesis
JNJ $235–$245 Cleanest large-cap healthcare. +24.2% above SMA200, golden cross, near 52wk high.
MRK $115–$121 Keytruda oncology growth. Strong-up, +23.3% alpha1Y. Pullback to SMA20 zone.
PFE $26.50–$28.50 Near 52wk high — any dip is the entry. Post-COVID transformation + Seagen.
LLY $895–$920 Critical SMA200 test. GLP-1 decade-defining franchise. Buy here or regret.
GILD $132–$140 HIV + antiviral moat. Golden cross, +12.8% above SMA200. 30D weakness = opportunity.
SYK $315–$330 RSI 30.6 approaching historical washout levels. Only for patient contrarian entry. Small position.

Action Matrix

Top Buys / Add

  1. JNJ — Best risk/reward in healthcare. Golden cross, +24.2% above SMA200, +33.5% alpha1Y. The bedrock holding.
  2. MRK — Keytruda franchise deserves premium. Strong-up, golden cross. Near 52wk high is a feature not a bug.
  3. PFE — Cheapest large-cap pharma near 52wk high. +13.8% in 3M with more pipeline catalysts ahead.
  4. LLY — Don't sell the GLP-1 franchise at SMA200. This is the buy point if you missed it all year.
  5. MRNA — mRNA revival is real. +69.8% in 3M. Strong-up, golden cross. Position for pipeline readouts.

Top Sells / Avoid

  1. UNH — -55.5% from 52wk high, regulatory/legal overhang structural. Death cross. Exit or avoid.
  2. VEEV — Healthcare cloud SaaS in full distribution. -43.8% from 52wk high, -30.3% below SMA200.
  3. ABT — RSI 27.9 extreme oversold, but structure fully broken. Death cross, -27% from 52wk high. Don't catch the knife.
  4. DXCM — CGM competition is a permanent headwind. Death cross, -29.6% from 52wk high.
  5. MDT — Medical device cycle grinding lower. Wait for a real base.

Key Observations

  • Traditional pharma (JNJ, MRK, PFE) is the healthcare flight-to-quality trade — large diversified pipelines, predictable earnings, dividend yields are getting rotation dollars from broken medtech/managed care.
  • UNH's -55.5% from 52wk high is a sector alarm — managed care model under existential pressure from regulatory scrutiny. The damage is structural, not cyclical.
  • LLY testing SMA200 ($894) is the most watched level in healthcare — the GLP-1 franchise is intact but near-term pricing/competition fears are real. This level is the thesis checkpoint.
  • Medtech (SYK, ISRG, MDT, ABT, DXCM) is in coordinated breakdown — medical device utilization fears + competitive pressure + valuation compression all at once.
  • MRNA's +69.8% in 3M stands alone as the sector's most explosive story. mRNA platform expanding beyond vaccines with RSV, flu, and cancer immunotherapy pipeline readouts ahead.
  • ABT at RSI 27.9 is technically extreme — watch for a dead-cat bounce. But with a death cross and -18% below SMA200, any bounce is for traders, not investors.

Data: 2026-03-31 pre-computed summaries (healthcare-scan.json).

10 events
DateTypeEvent
Apr 3 ScanHealthcare Scan Apr 10 ScanHealthcare Scan Apr 13 Scan2 — HEALTHCARE SCAN Apr 26 ScanHealthcare Scan Apr 28 ScanHealthcare Scan Mar 26 ScanHealthcare Scan Mar 24 ScanHealthcare Scan Mar 20 ScanHealthcare Scan May 29 ScanHealthcare Scan Mar 13 ScanHealthcare Scan

No direct external sources are attached to this read.